LRG1 antibody (AA 41-257)

Catalog No. ABIN7874832

The Rabbit Polyclonal anti-LRG1 antibody is suitable to detect LRG1 in samples from Human, Rat and Mouse. It has been validated for WB, IHC and ELISA.

Quick Overview for LRG1 antibody (AA 41-257) (ABIN7874832)

Target: LRG1 (Leucine-Rich alpha-2 Glycoprotein 1 (LRG1))

Reactivity: Human, Rat, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This LRG1 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA

Product Details anti-LRG1 Antibody

Binding Specificity: AA 41-257

Purpose: LRG1 Antibody / Leucine-rich alpha-2-glycoprotein 1

Purification: Immunogen affinity purified

Immunogen: E.coli-derived human LRG1 recombinant protein (Position: K41-Q257) was used as the immunogen for the LRG1 antibody.

Isotype: IgG

Application Details

Application Notes: Optimal dilution of the LRG1 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

Storage: 4 °C,-20 °C

Storage Comment: After reconstitution, the LRG1 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Target Details for LRG1

Target: LRG1 (Leucine-Rich alpha-2 Glycoprotein 1 (LRG1))

Alternative Name: LRG1

Background: LRG1 antibody detects Leucine-rich alpha-2-glycoprotein 1, a secreted glycoprotein that regulates angiogenesis, inflammation, and tissue remodeling. The UniProt recommended name is Leucine-rich alpha-2-glycoprotein 1 (LRG1). This plasma protein belongs to the leucine-rich repeat (LRR) family and interacts with transforming growth factor-beta (TGF-beta) signaling pathways to influence vascular and immune responses.

Functionally, LRG1 antibody identifies a 312-amino-acid glycoprotein composed of eight leucine-rich repeats forming a curved solenoid structure. LRG1 modulates endothelial cell behavior by binding endoglin and shifting TGF-beta signaling from the ALK5/SMAD2/3 axis to the ALK1/SMAD1/5/8 pathway, promoting angiogenesis. It also serves as an acute-phase reactant, increasing during infection, inflammation, and tissue injury.

The LRG1 gene is located on chromosome 19p13.3 and is highly expressed in liver, endothelial cells, and neutrophils. LRG1 is secreted into plasma, cerebrospinal fluid, and extracellular matrix, where it influences cell adhesion, migration, and vascular remodeling. Elevated serum LRG1 is a biomarker of cardiovascular and inflammatory diseases.

Pathologically, dysregulation of LRG1 contributes to diabetic retinopathy, fibrosis, tumor angiogenesis, and inflammatory disorders. Overexpression of LRG1 promotes abnormal vessel formation and tissue remodeling, while inhibition can suppress pathological angiogenesis. Research using LRG1 antibody supports studies in vascular biology, immunology, and biomarker discovery.

LRG1 antibody is validated for ELISA, western blotting, and immunohistochemistry to detect secreted and tissue-associated glycoproteins. NSJ Bioreagents provides LRG1 antibody reagents optimized for studies of angiogenesis, extracellular signaling, and disease pathophysiology.

Structurally, Leucine-rich alpha-2-glycoprotein 1 adopts a horseshoe-shaped LRR domain that mediates protein-protein interactions with growth factors and receptors. This antibody enables investigation of LRG1's role in vascular signaling and disease progression.

UniProt: P02750

Pathways: Brown Fat Cell Differentiation